Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B

BACKGROUND AND AIM: Hepatocellular carcinoma development can be decreased by achieving and maintaining complete virological response (CVR) in chronic hepatitis B. However, it is unclear whether switching from entecavir (ETV) to tenofovir alafenamide (TAF) could achieve and maintain CVR in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishido, Shun, Tamaki, Nobuharu, Uchihara, Naoki, Suzuki, Keito, Tanaka, Yuki, Miyamoto, Haruka, Yamada, Michiko, Matsumoto, Hiroaki, Nobusawa, Tsubasa, Keitoku, Taisei, Takaura, Kenta, Tanaka, Shohei, Maeyashiki, Chiaki, Yasui, Yutaka, Takahashi, Yuka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Kurosaki, Masayuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463023/
https://www.ncbi.nlm.nih.gov/pubmed/37649865
http://dx.doi.org/10.1002/jgh3.12950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463023/
https://www.ncbi.nlm.nih.gov/pubmed/37649865
http://dx.doi.org/10.1002/jgh3.12950

Ejemplares similares